Dmitri B Kirpotin
Overview
Explore the profile of Dmitri B Kirpotin including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
43
Citations
2303
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Kirpotin D, Hayes M, Noble C, Huang Z, Wani K, Moore D, et al.
J Pharm Sci
. 2022 Dec;
112(2):416-434.
PMID: 36462709
Therapeutics at or close to the nanoscale, such as liposomal irinotecan, offer significant promise for the treatment of solid tumors. Their potential advantage over the unencapsulated or free form of...
2.
Geddie M, Kirpotin D, Kohli N, Kornaga T, Boll B, Razlog M, et al.
MAbs
. 2022 Jun;
14(1):2083466.
PMID: 35708974
Antibody-directed nanotherapeutics (ADNs) represent a promising delivery platform for selective delivery of an encapsulated drug payload to the site of disease that improves the therapeutic index. Although both single-chain Fv...
3.
Kamoun W, Swindell E, Pien C, Luus L, Cain J, Pham M, et al.
Pharmaceutics
. 2020 Oct;
12(10).
PMID: 33092175
Ephrin receptor A2 (EphA2) is a member of the Ephrin/Eph receptor cell-to-cell signaling family of molecules, and it plays a key role in cell proliferation, differentiation, and migration. EphA2 is...
4.
Huang Z, Tipparaju S, Kirpotin D, Pien C, Kornaga T, Noble C, et al.
J Control Release
. 2019 Aug;
310:47-57.
PMID: 31400383
Ephrin A2 targeted immunoliposomes incorporating pH-sensitive taxane prodrugs were developed for sustained delivery of active drug to solid tumors. Here we describe the systematic formulation development and characterization of these...
5.
Kamoun W, Kirpotin D, Huang Z, Tipparaju S, Noble C, Hayes M, et al.
Nat Biomed Eng
. 2019 Apr;
3(4):264-280.
PMID: 30952988
Antibody-mediated tumour targeting and nanoparticle-mediated encapsulation can reduce the toxicity of antitumour drugs and improve their efficacy. Here, we describe the performance of a nanotherapeutic encapsulating a hydrolytically sensitive docetaxel...
6.
Lee H, Shields A, Siegel B, Miller K, Krop I, Ma C, et al.
Clin Cancer Res
. 2017 Mar;
23(15):4190-4202.
PMID: 28298546
Therapeutic nanoparticles are designed to deliver their drug payloads through enhanced permeability and retention (EPR) in solid tumors. The extent of EPR and its variability in human tumors is highly...
7.
Geddie M, Kohli N, Kirpotin D, Razlog M, Jiao Y, Kornaga T, et al.
MAbs
. 2016 Nov;
9(1):58-67.
PMID: 27854147
Antibody-targeted nanoparticles have great promise as anti-cancer drugs; however, substantial developmental challenges of antibody modules prevent many candidates from reaching the clinic. Here, we describe a robust strategy for developing...
8.
Zhang K, Geddie M, Kohli N, Kornaga T, Kirpotin D, Jiao Y, et al.
MAbs
. 2014 Dec;
7(1):42-52.
PMID: 25484041
Antibody-targeted nanoparticles have the potential to significantly increase the therapeutic index of cytotoxic anti-cancer therapies by directing them to tumor cells. Using antibodies or their fragments requires careful engineering because...
9.
Noble C, Krauze M, Drummond D, Forsayeth J, Hayes M, Beyer J, et al.
Nanomedicine (Lond)
. 2014 Feb;
9(14):2099-108.
PMID: 24494810
Aim: We sought to evaluate nanoliposomal irinotecan as an intravenous treatment in an orthotopic brain tumor model. Materials & Methods: Nanoliposomal irinotecan was administered intravenously in the intracranial U87MG brain...
10.
Weng K, Hashizume R, Noble C, Serwer L, Drummond D, Kirpotin D, et al.
Nanomedicine (Lond)
. 2013 May;
8(12):1913-25.
PMID: 23631502
Aim: The aim of this work is to evaluate combining targeting strategy and convection-enhanced delivery in brain tumor models by imaging quantum dot-immunoliposome hybrid nanoparticles. Materials & Methods: An EGF...